WO2006071095A1 - Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité - Google Patents

Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité Download PDF

Info

Publication number
WO2006071095A1
WO2006071095A1 PCT/KR2005/004664 KR2005004664W WO2006071095A1 WO 2006071095 A1 WO2006071095 A1 WO 2006071095A1 KR 2005004664 W KR2005004664 W KR 2005004664W WO 2006071095 A1 WO2006071095 A1 WO 2006071095A1
Authority
WO
WIPO (PCT)
Prior art keywords
amine compound
alkyl
compound
phenylquinazolino
ylquinazolino
Prior art date
Application number
PCT/KR2005/004664
Other languages
English (en)
Inventor
Nam Kyu Lee
Jun Won Lee
Sukho Lee
Guang-Jin Im
Hye Young Han
Tae Kon Kim
Yong Hyuk Kim
Wie-Jong Kwak
Sang Woong Kim
Joohun Ha
Eon Kyum Kim
Jung Kyu Lee
Choong Yeul Yoo
Dae Yeon Lee
Original Assignee
Sk Chemicals Co., Ltd.
Leadgenex Inc.
Industry Academic Cooperation Foundation Of Kyunghee University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co., Ltd., Leadgenex Inc., Industry Academic Cooperation Foundation Of Kyunghee University filed Critical Sk Chemicals Co., Ltd.
Priority to JP2007549270A priority Critical patent/JP2008526734A/ja
Priority to EP05823851A priority patent/EP1844023A1/fr
Publication of WO2006071095A1 publication Critical patent/WO2006071095A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and reducing body weight, and a preparation for treatment and/ or prevention of diabetes and/ or obesity, which comprises the compound as an active ingredient.
  • Diabetes one of the most common modern diseases, is on the increase in Korea, too. Because of its severe symptoms and sequela, the disease is becoming a social problem. Improvement of living standards and environments resulting form economic development has led to lack of exercises, while calorie intake has increased significantly. As a result, obesity and type 2 diabetes are also on the increase. If diabetes persists, blood lipid level increases, not to mention the blood glucose level, leading to cardiovascular diseases such as arteriosclerosis and coronary heart disease and complications such as diabetic kidney and retinal diseases. Therefore, development of a treatment for the above disease is an important issue.
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • Insulin secretory defect refers to the condition in which the beta cells of the pancreas cannot secrete an adequate amount of insulin depending on the blood glucose level and includes both quantitative and functional secretory defects.
  • Insulin resistance refers to the condition in which target cells fail to respond to ordinary levels of circulating insulin. The cause of insulin resistance is generally thought of as hindered signal transfer after binding to the cell membrane receptor, resulting from genetic factors, obesity, reduced physical activity, hyperglycemia, abnormal blood lipid level, etc. What is important is that the two factors are related with each other. If there is insulin resistance, more insulin has to be secreted to overcome the resistance. And, hyperglycemia caused by insufficient secretion of insulin may aggravate the insulin resistance.
  • type 2 diabetes is related with obesity, but the exact mechanism of the interaction or interrelationship still needs to be elucidated.
  • the focus of the research on the cause of diabetes has recently shifted from "glucose metabolism” to "fatty acid metabolism.”
  • type 2 diabetes patients such lipid metabolism disturbances as increase in blood fatty acid level, increase in neutral fats, decrease in high-density lipoprotein cholesterol, accumulation of fats in muscles, increase in abdominal fats and fatty liver are frequently found, as well as hyperglycemia.
  • insulin resistance is thought to be the most important pathological cause of NIDDM. Insulin resistance is the condition in which glucose is not fully utilized even when there is a sufficient amount of insulin.
  • various hypoglycemic drugs are used to treat insulin resistance. The hypoglycemic drugs are classified as follows depending on the treatment mechanism and the target site:
  • Sulfonylurea based drugs promote the movement of insulin-containing granules in the beta cells of the pancreas, thereby promoting the secretion of insulin at second hand.
  • Sulfonylurea based drugs promote the movement of insulin-containing granules in the beta cells of the pancreas, thereby promoting the secretion of insulin at second hand.
  • Biguanide based drugs transfer glucose to muscle cells and inhibit gluconeogenesis in the liver. They are advantageous in that they do not cause hypoglycemia, but care should be taken for aged people and patients with cardiovascular diseases.
  • ⁇ -Glucosidase inhibitors inhibit the enzymatic action of glucose production in the small intestine, preventing abrupt increase of blood glucose level after meals. With few side effects, the drugs are used to treat mild cases of diabetes.
  • thiazolidione (TZD) based drugs are known to activate PPAR- ⁇ , which participates in the differentiation of fat cells.
  • these oral hypoglycemic drugs are not so effective in reducing blood glucose level and cause side effects, development of safer diabetic treatments is imminent.
  • search for new target proteins capable of regulating the signal transfer system and metabolism processes is essential for development of such treatment drugs.
  • AMPK 5'AMP-activated protein kinase
  • AMPK plays a variety of other roles in the body. Besides controlling insulin production in pancreatic cells, it inhibits activation of acetyl CoA carboxylase
  • ACC HMG-CoA reductase
  • AMPK plays a key role in energy homeostasis control and carbohydrate and lipid metabolism control, as activated by AMFs accumulated by muscle contraction, exercise or energy depletion in cells. Also, it is viewed as new target material for treating metabolic diseases, such as diabetes and obesity, caused by energy imbalance.
  • metabolic diseases such as diabetes and obesity
  • the importance of AMPK in glucose absorption during exercise is widely known.
  • the fact that the action of AMPK is independent of the insulin signal transfer system means that it can become a new target material for treatment of type 2 diabetics, most of whom show troubles with the insulin signal transfer system. Actually, a lot of type 2 diabetics could reduce their blood glucose level through exercise and the diabetic model animal test confirmed that exercise promotes activation of AMPK and decrease in blood glucose level.
  • metformin or thiazolidinedione (TZD) based drugs which are widely used as diabetic treatments at present, reduce blood sugar level partly by an AMPK-involved mechanism.
  • search of the drugs that can activate AMPK will lead to the development of a new-concept treatment that imitates the therapeutic effect of exercise on a variety of metabolic diseases.
  • the present inventors synthesized a novel material that has a remarkable effect in increase of AMPK activity and prevention and/ or treatment of obesity and diabetes and confirmed the effect.
  • the present inventors synthesized several compounds with quinazoline backbones and confirmed that they are superior in reducing blood glucose level and body weight.
  • a novel quinazoline compound effective in reducing blood sugar level and body weight, which is essential in treating diabetes and obesity.
  • a treatment for diabetes and obesity with no toxicity or side effects which comprises the novel quinazoline compound, a pharmaceutically available salt thereof or a pharmaceutically available prodrug thereof as an active ingredient.
  • the present invention relates to a quinazoline derivative, a pharmaceutically available salt thereof or a pharmaceutically available prodrug thereof effective in treating diabetes and obesity, which is represented by the formula 1 below:
  • R a is a substituent selected from hydrogen, (Ci-Ci8)alkyL (C 2 -Cs) alkenyl, (C2-C8)alkynyl, halogeno-(Ci-C6)alkyl, hydroxy-(Ci-C6)alkyl, (Ci-C6)alkoxy-(Ci-C6)alkyl, cyano-(Ci-C 6 )alkyl, amino-(Ci-C 6 )alkyl, (Ci-C6)alkylamino-(C 1 -C6)alkyl, di-[(Ci-C6)alkyl]amino-(Ci-C6)alkyl, (Ci-C6)alkylthio-(Ci-C 6 )alkyl / (Ci-C 6 )alkylsulfinyl-(Ci-C6)alkyl and (Ci-C 6 )alkylsulfonyl-(Ci-C6)alkyl
  • N-(Ci-C 6 )alkylsulfamoyl N,N-di-[(Ci-C 6 )alkyl]sulfamoyl
  • X 3 is a direct bonding or selected from O, S, SO, SO 2 , N(R 7 ), CO, CH(OR 7 ), CON(R 7 ), N(R 7 )CO, SO 2 N(R 7 ), N(R 7 )SO 2 , C(R 7 ) 2 O, C(R 7 ) 2 S, N(R 7 )C(R 7 ) 2 ,
  • R 7 is a hydrogen atom, (Ci-C 6 )alkyl, aryl, aryl-(C 1 -C 6 )alkyl / (C 3 -C 7 )CyClOaIlCyI, (C3-C 7 )cycloalkyl-(C 1 -C 6 )alkyl /
  • any aryl, heteroaryl or heterocyclyl of R a may have 0 to 3 substituents, which may be identical or different and are selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxyl, carbamoyl, (Ci-C6)alkyl, (C2-Cs)alkenyl, (C2-C8)alkynyl, (Ci-C 6 )alkoxy, (C2-C6)alkenyloxy, (C2-C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfiny
  • X 4 is a direct bonding or selected from O and N(R 9 ), wherein R 9 is a hydrogen atom or (Ci-C ⁇ )alkyl, and R 8 is selected from halogeno-(C 1 -C ⁇ )alkyl, hydroxy-(Ci-C6)alkyl
  • R b is a substituent selected from hydrogen, (C2-Cs)alkenyl, (C 2 -C 8 )alkynyl, halogeno-(d-C6)alkyl, hydroxy-(Ci-C 6 )alkyl,
  • (Ci-C 6 )alkylamino-(Ci-C 6 )alkyl di-[(Ci-C 6 )alkyl]amino-(Ci-C 6 )alkyl, (Ci-C 6 )alkylthio-(Ci-C 6 )alkyl, (Ci-C 6 )alkylsulfinyl-(Ci-C 6 )alkyl or
  • X 1 is a direct bonding or selected from O, S, SO, SO 2 , N(R 4 ), CO, CO 2 (R 4 ), CH(OR 4 ), CON(R 4 ), N(R 4 )CO, SO 2 N(R 4 ), N(R 4 )SO 2 , C(R 4 ) 2 O, C(R 4 ) 2 S, N(R 4 )C(R 4 ) 2 , N(R 4 )CON(R 4 ) and N(R 4 )CSN(R 4 ), wherein R 4 is a hydrogen atom, (Ci-QJalkyl, aryl, aryl-(Ci-C 6 )alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(Ci-C6)alkyl, (C3-C7)
  • X 3 is a direct bonding or selected from O, S, SO, SO 2 , N(R 7 ), CO, CH(OR 7 ), CON(R 7 ), N(R 7 )CO, SO 2 N(R 7 ), N(R 7 )SO 2 , C(R 7 ) 2 O, C(R 7 ) 2 S, N(R 7 )C(R 7 ) 2 , N(R 7 )CON(R 7 ) and N(R 7 )CSN(R 7 ), wherein R 7 is a hydrogen atom, (Ci-C 6 )alkyl,
  • X 4 is a direct bonding or selected from O and N(R 9 ), wherein R 9 is a hydrogen atom or (Ci-C6)alkyl, and R 8 is selected from halogeno-(Ci-C6)alkyl, hydroxy-(Ci-C6)alkyl
  • CH 2 or HC ⁇ , selected from halogeno, carboxyl, carbamoyl, (Ci-C6)alkoxycarbonyl, N-(Ci-C6)alkylcarbamoyl, N,N-di-[(Ci-C6)alkyl]carbamoyl, amino-(Ci-C6)alkyl, (Ci-C 6 )alkylamino-(Ci-C6)alkyl and di-[(Ci-C 6 )alkyl]amino-(C 1 -C 6 )alkyl or -Q 5 -X 6 [wherein X 6 is a direct bonding or selected from CO and N(R 13 )CO, wherein R 13 is a hydrogen atom or (Ci-C 6 )alkyl, and Q 5 is aryl, aryl-(Ci-C6)alkyl, heteroaryl, heteroaryl-(C; ⁇ -C6)alkyl, heterocyclyl or heterocyclyl
  • any aryl, heteroaryl or heterocyclyl of R c may have 1, 2 or 3 identical or different substituents selected from hydrogen, halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxyl, carbamoyl, (Ci-C6)alkyl, (C 2 -Cs) alkenyl, (C2-C8)alkynyl, (Ci-C6)alkoxy, (C 2 -C ⁇ )alkenyloxy, (C 2 -C 6 ) alky nyloxy, (Ci-C 6 )alkylthio, (Ci-C6)alkylsulfinyl, (C 1 -C 6
  • N-(Ci-C6)alkyl-(C3-C 6 )alkynoylamino N-(Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C 1 -C 6 )alkanesulfonylamino and
  • X 8 is a direct bonding or selected from O and N(R 16 ), wherein R 16 is a hydrogen atom or (Ci-C 6 )alkyl
  • R 15 is selected from halogeno-(Ci-C6)alkyl, hydroxy-(Ci-C6)alkyl, (Ci-C 6 )alkoxy-(Ci-C6)alkyl, cyano-(Ci-C 6 )alkyl, amino-(Ci-C6)alkyl, (Ci-C 6 )alkylamino-(C 1 -C 6 )alkyl and di-[(Ci-C 6 )alkyl]amino-(Ci-C 6 )alkyl or -X 9 -Q 7
  • X is a direct bonding or selected from O, S, SO, SO 2 and NR 5 , wherein R 5 is a hydrogen atom, (C 1 -C 6 )alkyl, aryl, aryl-(Ci-C6)alkyl, (C3-C7)cycloalkyl, (C 3 -C7)cycloalkyl-(Ci-C6)alkyl, heteroaryl, heteroaryl-(Ci-C6)alkyl, heterocyclyl or heterocyclyl-(Ci-C ⁇ )alkyl;
  • Ri is a substituent selected from hydrogen, (Ci-C8)alkyl, halogeno-(Ci-C 6 )alkyl, hydroxy-(d-C 6 )alkyl, (Ci-C 6 )alkoxy-(C 1 -C 6 )alkyl / amino-(Ci-C6)alkyl, (Ci-C6)alkylamino-(Ci-C 6 )alkyl, di-[(C 1 -C 6 )alkyl]amino-(C 1 -C 6 )alkyl and (Ci-C 6 )alkylsulfinyl or -X ⁇ -Q 1 [wherein X 1 is a direct bonding or selected from O, S and NR 5 and Q 1 and R 5 may be identical or different], the neighboring carbon atoms of (C2-C 6 )alkylene of Ri may be separated by a group selected from O, S and N(R 5 ), any CH 2 or CH3 of R 1 may
  • (C 1 -C6)alkoxycarbonyl, N-(d-C6)alkylcarbamoyl and N,N-di-[(C 1 -C6)alkyl]carbamoyl and heterocyclyl of R3 and R 4 may have 1 or 2 oxo or thioxo substituents.
  • X is O, S or NR 5 ;
  • R 1 is a hydrogen atom, C 1 -C 6 alkyl, C 1 -C 4 haloalkyl, C 1 -C 6 alkylhydroxy,
  • R 2 is Ci-Ci 8 alkyl, C 2 -C 8 haloalkyl, C 3 -C 7 cycloalkyl, (C 3 -C 7 )cycloalkyl
  • the compound represented by the formula 1 may form a pharmaceutically available salt, including an inorganic acid salt such as hydrochloride, sulfate, phosphate, bisphosphate, hydrobromate and nitrate or an organic acid salt such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate and stearate.
  • an inorganic acid salt such as hydrochloride, sulfate, phosphate, bisphosphate, hydrobromate and nitrate
  • an organic acid salt such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate and stearate.
  • Some of the compounds of the present invention may be crystallized or recrystallized using an aqueous or organic solvent. In that case, a solvate may be formed.
  • hydrates and other stoichiometric solvates belong to the scope of the present invention.
  • the compound represented by the formula 1 may be an enantiomer, a stereoisomer or a tautomer.
  • the isomers may be separated or decomposed by common methods or may be obtained by common stereospecific or asymmetrical synthesis methods.
  • the present invention also provides a preparation method of the quinazoline derivatives represented by the formula 1 and a pharmaceutically available salt thereof.
  • the present invention also provides a preparation method of the compound represented by the formula 1-1. As shown in the scheme 1 below, it may be synthesized from the subs titution reaction of a 4-chloro-2-substituted-quinazoline derivative represented by the formula 2 below and a compound represented by the formula 3 below: Scheme 1
  • the substitution reaction of the scheme 1 is carried out in the presence of a base and an organic polar solvent.
  • a base an organic base such as pyridine or an alkylamine or an inorganic base such as an alkali metal salt or an alkaline earth metal salt may be used.
  • the compound represented by the formula 1-1 may be prepared from the substitution reaction of a 2-chloro-4-substituted-quinazoline derivative represented by the formula 4 below and a compound represented by the formula 5 below, as shown in the scheme 2 below:
  • the substitution reaction of the scheme 2 is carried out in the presence of a base and an organic polar solvent.
  • a base an organic base such as pyridine or an alkylamine or an inorganic base such as an alkali metal salt or an alkaline earth metal salt may be used.
  • the compound represented by the formula 1-1 may be prepared from the substitution reaction of a 2-methyl-3H-quinazolino-4-one derivative represented by the formula 6 below, which is substituted by X at the number 4 position, and a compound represented by the formula 7 below, as shown in the scheme 3 below:
  • the substitution reaction of the scheme 3 is carried out in the presence of a base and an organic polar solvent.
  • a base an organic base such as pyridine or an alkylamine or an inorganic base such as an alkali metal salt or an alkaline earth metal salt may be used.
  • the compounds represented by the formulas 2 and 3 in the scheme 1, which are used as starting materials of the substitution reaction, may be prepared by the methods well known in the field of organic synthesis.
  • 2-ethylsulfanyl-3H-quinazolino-4-one is added thionyl chloride (SOCb) at -20 to 10 °C and reflux reaction is performed in the presence of an N,N-dimethylformamide catalyst in order to transform the ketone group at the C-4 position into chlorine (Cl).
  • SOCb thionyl chloride
  • R3 and R 4 are the same as defined in the formula 1.
  • an imidate compound is reacted with anthranilic acid and sodium methoxide (NaOMe) in the temperature range from room temperature to the reflux temperature of the solvent while stirring in order to prepare 3H-quinazolino-4-one with the substituent R 1 .
  • NaOMe sodium methoxide
  • phosphorus oxy chloride and diethylaniline are added and reaction is carried out in the temperature range from room temperature to the reflux temperature of the solvent while stirring to transform the ketone group at the C-4 position into chlorine (Cl).
  • R 1 is a hydrogen atom
  • alkyl or aryl may also be prepared by the scheme 6 below:
  • R 1 , R3 and R 4 are the same as defined in the formula 1.
  • an acyl halide is reacted with anthranyl amide and reflux reaction is carried out in the presence of NaOH to prepare 3H-quinazolino-4-one with the substituent R 1 .
  • phosphorus oxy chloride and diethylaniline are added and reaction is performed in the temperature range from room temperature to the reflux temperature of the solvent while stirring in order to transform the ketone group at the C-4 position into chlorine (Cl).
  • the compounds represented by the formulas 4 and 5 in the scheme 2, which are used as starting materials of the substitution reaction, may be prepared by the methods well known in the field of organic synthesis.
  • the compound represented by the formula 4 may be prepared by the scheme 7 below:
  • R 2 , R3, R4 and X are the same as defined in the formula 1.
  • the compound represented by the formula 3 may be used in excess as both organic solvent and reactant or another solvent may be used and the compound may be used stoichiometrically. And the reaction may be carried out in the presence of a base, if deemed necessary.
  • a base an organic base such as pyridine and an alkylamine or an inorganic base such as an alkali metal salt and an alkaline earth metal salt may be used.
  • the prepared intermediate compound and the target compound may be separated and purified by such common methods as chromatography and recrystallization.
  • the compounds of the present invention may be administered by an adequate administration method, for example, orally, intraorally, sublingually, rectally, vaginally, intranasally, locationally or non-orally (including intravenously, intracavernously, intramuscularly, subcutaneously and intraluminally).
  • an adequate administration method for example, orally, intraorally, sublingually, rectally, vaginally, intranasally, locationally or non-orally (including intravenously, intracavernously, intramuscularly, subcutaneously and intraluminally).
  • the general dosage of the compound represented by the formula 1 for treatment or prevention of diabetes and obesity is 0.1 to 400 mg/day for an adult weighing 70 kg.
  • the compound can be prepared into a tablet or capsule, using a pharmaceutically available excipient or vehicle, with the content of the compound of 0.05 to 200 mg, and administered once or several times a day.
  • the compound is administered in an amount of 0.01 to 100 mg.
  • the adequate dosage is determined by the doctor, considering the patient's age, body weight and other characteristics.
  • the aforementioned dosages are for general cases.
  • the dosage may be higher or lower from a patient to another.
  • the compound represented by the formula 1 may be administered alone or along with a pharmaceutical vehicle that is selected in consideration of the administration and other standard pharmaceutical practices.
  • the compound may be administered orally, intraorally or sublingually in the form of a tablet containing starch or lactose, ovules by itself or along with excipients or elixir or emulsion containing chemicals that offer specific flavors or colors.
  • the liquid preparation may be prepared by adding a pharmaceutically available additive such as a suspension (e.g., a mixture of semisynthetic glyceride like methylcellulose and witepsol or apricot kernel oil with PEG-6 ester or a glyceride mixture of PEG-8 and caprylic/capric glyceride). It may be administered non-orally, for example, intravenously, intracavernously, intramuscularly, subcutaneously or intraluminally. For non-oral administration, it is most preferable to use the compound in the form of sterile aqueous solution.
  • the solution may comprise other substances (for example, salts or monosaccharides such as mannitol and glucose) for isotonicity with blood.
  • the present invention provides a pharmaceutical composition comprising the compound represented by the formula 1 or a pharmaceutically available salt thereof, as an active ingredient, and a pharmaceutically available diluent or excipient.
  • the present invention also provides a pharmaceutical composition for medical use comprising the compound represented by the formula 1, a pharmaceutically available salt thereof or a pharmaceutically available prodrug thereof as an active ingredient.
  • FIG. 1 shows the result of Western blot analysis showing the degree of phosphorylation of the serine-79 for the compound of the present invention.
  • FIGs. 2a to 2g show the results of Western blot analysis showing the degree of phosphorylation of the serine-79 and threonine-172 for the compound of the present invention.
  • FIGs. 3a and 3b are graphs showing the change of blood glucose level when the compound of the present invention was abdominally administered to db/db mice.
  • FIGs. 4a and FIG. 4b are graphs showing the change of body weight when the compound of the present invention was abdominally administered to db/db mice.
  • FIGs. 5a, 5b and 5c are graphs showing the change of blood glucose level when the compound of the present invention was orally administered to db/db mice.
  • FIGs. 6a, 6b and 6c are graphs showing the change of body weight when the compound of the present invention was orally administered to db/db mice.
  • FIGs. 7a and 7b are graphs showing the change of body weight when the compound of the present invention was abdominally administered to ob/ob mice.
  • FIGs. 8a and 8b are graphs showing the change of blood glucose level when the compound of the present invention was abdominally administered to ob/ob mice.
  • FIG. 9 is a graph showing the change of body weight when the compound of the present invention was orally administered to ob/ob mice.
  • Example 4 Preparation of 4-substituted amine-2-phenylquinazoline (formula Ib) 4-Chloro-2-phenylquinazoline (formula 2b; 0.5 g, 2.08 mmol) was dissolved in 30 mL of THF. TEA (5 eq, 1.45 mL, 10.38 mmol) and amine (1.5 eq) were added and the mixture was stirred at room temperature overnight. When the starting materials disappeared, THF was removed by distillation under reduced pressure and the target compound was obtained with a yield of 90 % by column chromatography (silica gel; 230-400 mesh).
  • Example 9 Preparation of 2-substituted-3H-quinazolino-4-one (formula E) 2-(Substituted-carbonyl-amino)-benzamide (formula H; 45 mmol) was dissolved in 60 mL of 2.5N-NaOH and the mixture was refluxed for 1 hour. When the starting materials disappeared, the mixture was cooled to 0 "C and neutralized with 3N-HC1. The formed crystal was filtered and dried to obtain the target compound with a yield of 95 % (43 mmol).
  • the mixture was stirred at room temperature for 3 hours and ethanol was removed by distillation under reduced pressure when the starting materials disappeared.
  • the compound represented by the formula 1 may be prepared into a variety of preparation forms depending on the purpose. The following are non-limiting examples of some preparation forms comprising the compound represented by the formula 1 as an active ingredient.
  • a tablet for oral administration was prepared by wet granulation and dry granulation.
  • composition Active ingredient 200 mg, hard silicic anhydride 10 mg, magnesium stearate
  • composition Active ingredient 100 mg, mannitol 180 mg, dibasic sodium phosphate 25 mg, water for injection 2974 mg.
  • Experimental Example 1 Analysis of glucose absorption
  • C2C12 muscle cells were cultured in DMEM (Dulbecco's modified Eagle's medium) containing 10 % bovine calf serum. When the cell density increased to about 85 to 90 %, the culture medium was replaced with 1 % bovine calf serum and cell differentiation was induced for 6 days. Completely differentiated cells were cultured for 3 hours with Krebs-Ringer buffer (KRB) containing 5 mM glucose. The test materials were added at a concentration of 10 ⁇ M. 30 minutes later, 0.2 ⁇ Ci 2-deoxyglucose was added. KRB was removed 20 minutes later and the cells were washed for 3 times with cold PBS. The cells were lysed with 0.5N NaOH and counted using a radioactive counter.
  • KRB Krebs-Ringer buffer
  • C2C12 cells were cultured and differentiated in the same manner as in Experimental Example 1. Treatment with the test materials was also performed in the same manner as in Experimental Example 1 (10 ⁇ M for 50 minutes). The culture medium was removed and the cells were washed for 2 times with PBS and protein extracts were obtained using a lysis buffer (50 mM tris-HCl, pH 7.4, 1 % NP-40, 0.25 % sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM sodium o-vanadate, 1 mM NaF, 1 ⁇ g/ mL apronitin, 1 ⁇ g/mL leu-peptin, 1 ⁇ g/mL pepstatin). The AMPK activity was determined from Western blot analysis of the degree of phosphorylation of serine-79 by acetyl CoA carboxylase and the degree of phosphorylation of threonine-172. The amount of ERK
  • CMC carboxylmethylcellulose
  • CMC rosiglitazone dissolved in 0.5 % carboxylmethylcellulose
  • test material were administered orally or abdominally every afternoon to the negative control group, the positive control group and the test group, respectively.
  • Blood glucose level measurement was made just before the administration, at an interval of 3-4 days, by incising the tail vein. Body weight and the amount of feed were measured every day just before the administration.
  • test group to which the compound represented by the formula 1 had been administered abdominally or orally showed significant decrease in blood glucose level and body weight compared with the control group, which implies the preventive and therapeutic effect for diabetes and obesity.
  • mice 6- week old male ob/ob mice (Harlan) were accustomed to the environment of the animal breeding facility of SK for a week. During the period, the mice were freely given feed and water. The mice were grouped based on the body weight. The mice were grouped into the control group, the positive control group (sibutramine) and the test group. The administration dosage was 15 mg/kg for the positive control group and 200 mg/kg/10 mL for the test group. Administration was given abdominally using an insulin syringe. Administration was given once a day at 5 p.m. over a 4-week period. The control group was administered with 0.5 % carboxymethyl cellulose (CMC), at kg/ 1O mL.
  • CMC carboxymethyl cellulose
  • Body weight was measured over the 4-week period. The difference in the body weight of the control group and the body weight of the test group (g) and the increase of the body weight (%) were calculated to evaluate the inhibitive effect against body weight increase. Also, the amount of feed intake was measured in order to evaluate the inhibitive effect against feed intake.
  • Oral administration test was performed for the materials that showed effectiveness in Experimental Example 1. Grouping of the mice, administration dosage, administration period, etc. were the same as in Experimental Example 3-1. Forced oral administration was performed using a bouige.
  • FIGs. 8a and 8b and FIG. 9 the test group to which the compound represented by the formula 1 had been administered abdominally or orally showed significant decrease in blood glucose level and body weight compared with the control group, which implies the preventive and therapeutic effect for diabetes and obesity.
  • the compounds of the present invention are effective in lowering blood glucose level and body weight and can be used for treatment of diabetes and/ or obesity.

Abstract

La présente invention concerne de nouveaux dérivés de quinazoline qui permettent de diminuer le taux sanguin de glucose ainsi que la masse corporelle. La présente invention concerne également un médicament pour le traitement prophylactique et/ou thérapeutique du diabète et/ou de l'obésité, et qui comprend lesdits composés au titre de principes actifs.
PCT/KR2005/004664 2004-12-31 2005-12-30 Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité WO2006071095A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007549270A JP2008526734A (ja) 2004-12-31 2005-12-30 糖尿及び肥満治療予防に有効なキナゾリン誘導体
EP05823851A EP1844023A1 (fr) 2004-12-31 2005-12-30 Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040117708 2004-12-31
KR10-2004-0117708 2004-12-31

Publications (1)

Publication Number Publication Date
WO2006071095A1 true WO2006071095A1 (fr) 2006-07-06

Family

ID=36615173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/004664 WO2006071095A1 (fr) 2004-12-31 2005-12-30 Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité

Country Status (4)

Country Link
EP (1) EP1844023A1 (fr)
JP (1) JP2008526734A (fr)
KR (1) KR20060079121A (fr)
WO (1) WO2006071095A1 (fr)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042669A2 (fr) * 2005-10-12 2007-04-19 Sanofis-Aventis DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl
WO2007071632A3 (fr) * 2005-12-20 2007-08-30 Neurosearch As Derives de pyridinyl-quinazoline et leur utilisation medicale
WO2008157500A1 (fr) * 2007-06-17 2008-12-24 Kalypsys, Inc. Modulateurs du récepteur cannabinoïde à base d'aminoquinazoline pour le traitement de maladies
WO2009000085A1 (fr) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Dérivés de quinoline et de quinazoline utiles comme modulateurs des canaux ioniques
WO2009131173A1 (fr) 2008-04-23 2009-10-29 協和発酵キリン株式会社 Dérivé de 2-aminoquinazoline
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP2011506480A (ja) * 2007-12-12 2011-03-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8212045B2 (en) 2007-09-21 2012-07-03 Array Biopharma, Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US20160159751A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN106045924A (zh) * 2016-07-28 2016-10-26 黑龙江八农垦大学 一种芳基取代喹唑啉胺衍生物的合成方法
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9624195B2 (en) 2014-12-24 2017-04-18 Gilead Sciences, Inc. Isoquinoline compounds
US9701677B2 (en) 2014-12-24 2017-07-11 Gilead Sciences, Inc. Fused pyrimidine compounds
US9730936B2 (en) 2014-12-24 2017-08-15 Gilead Sciences, Inc. Quinazoline compounds
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9802904B2 (en) 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US9873702B2 (en) 2014-12-05 2018-01-23 Southern Research Institute Heterocyclic compounds as biogenic amine transport modulators
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
WO2020021064A1 (fr) 2018-07-26 2020-01-30 Domain Therapeutics Dérivés de quinazolinone substitués et leur utilisation en tant que modulateurs allostériques positifs de mglur4
US10934284B2 (en) 2013-02-01 2021-03-02 Wellstat Therapeutics Corporation Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
CN112608302A (zh) * 2020-12-28 2021-04-06 郑州大学第一附属医院 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
CN114315802A (zh) * 2021-12-14 2022-04-12 西安医学院 一种喹唑啉含氮杂环衍生物及制备方法和用途
WO2022091029A1 (fr) * 2020-10-30 2022-05-05 Resverlogix Corp. Méthodes pour abaisser le taux d'hba1c avec une combinaison d'un inhibiteur de bromodomaine bet et d'un inhibiteur du transporteur de glucose dépendant du sodium 2
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590913A (en) * 2008-07-11 2012-09-28 Myrexis Inc (2-aminomethylquinazolin-4-yl)-(4-methoxyphenyl)methylamine for treating or ameliorating neoplasm or cancer
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
KR101467996B1 (ko) * 2010-04-30 2014-12-11 전북대학교산학협력단 에이디피-리보실 사이클라제 활성을 저해하는 퀴나졸린 유도체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013354A1 (fr) * 1996-09-25 1998-04-02 Zeneca Limited Derives quinazolines et compositions pharmaceutiques les contenant
WO2000010981A1 (fr) * 1998-08-21 2000-03-02 Parker Hughes Institute Derives de quinazoline
WO2000012497A2 (fr) * 1998-08-28 2000-03-09 Scios Inc. Derives de quinazoline utilisables comme medicaments
WO2004087680A1 (fr) * 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Nouveaux derives de quinazoline et leur utilisation therapeutique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
JPS542325A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
WO2002062767A1 (fr) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
DE10224462A1 (de) * 2002-06-03 2003-12-11 Bayer Ag Verwendung von cGMP stimulierenden Verbindungen
EP1610774A4 (fr) * 2003-04-09 2008-07-16 Exelixis Inc Modulateurs de tie-2 et procedes d'utilisation
WO2005003100A2 (fr) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Composes et leur utilisation therapeutique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013354A1 (fr) * 1996-09-25 1998-04-02 Zeneca Limited Derives quinazolines et compositions pharmaceutiques les contenant
WO2000010981A1 (fr) * 1998-08-21 2000-03-02 Parker Hughes Institute Derives de quinazoline
WO2000012497A2 (fr) * 1998-08-28 2000-03-09 Scios Inc. Derives de quinazoline utilisables comme medicaments
WO2004087680A1 (fr) * 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Nouveaux derives de quinazoline et leur utilisation therapeutique

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093273B2 (en) 2004-10-20 2012-01-10 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US8242130B2 (en) 2004-10-20 2012-08-14 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007042669A2 (fr) * 2005-10-12 2007-04-19 Sanofis-Aventis DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl
WO2007042669A3 (fr) * 2005-10-12 2007-05-31 Sanofis Aventis DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl
WO2007071632A3 (fr) * 2005-12-20 2007-08-30 Neurosearch As Derives de pyridinyl-quinazoline et leur utilisation medicale
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US9199990B2 (en) 2007-02-01 2015-12-01 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US10532054B2 (en) 2007-02-01 2020-01-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2008157500A1 (fr) * 2007-06-17 2008-12-24 Kalypsys, Inc. Modulateurs du récepteur cannabinoïde à base d'aminoquinazoline pour le traitement de maladies
WO2009000085A1 (fr) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Dérivés de quinoline et de quinazoline utiles comme modulateurs des canaux ioniques
US8212045B2 (en) 2007-09-21 2012-07-03 Array Biopharma, Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US8853409B2 (en) 2007-09-21 2014-10-07 Array Biopharma Inc. Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US9079890B2 (en) 2007-09-21 2015-07-14 Array Biopharma Inc. Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives
JP2011506480A (ja) * 2007-12-12 2011-03-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
WO2009131173A1 (fr) 2008-04-23 2009-10-29 協和発酵キリン株式会社 Dérivé de 2-aminoquinazoline
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US11407719B2 (en) 2009-03-18 2022-08-09 Resverlogix Corp. Anti-inflammatory agents
US10131640B2 (en) 2009-03-18 2018-11-20 Resverlogix Corp. Anti-inflammatory agents
US10882828B2 (en) 2009-03-18 2021-01-05 Resverlogix Corp. Anti-inflammatory agents
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US11008306B2 (en) 2009-09-03 2021-05-18 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9822096B2 (en) 2009-09-03 2017-11-21 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9458114B2 (en) 2009-09-03 2016-10-04 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US10214511B2 (en) 2009-09-03 2019-02-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US10676460B2 (en) 2009-09-03 2020-06-09 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US10016426B2 (en) 2011-11-01 2018-07-10 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9802904B2 (en) 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
US10934284B2 (en) 2013-02-01 2021-03-02 Wellstat Therapeutics Corporation Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US9873702B2 (en) 2014-12-05 2018-01-23 Southern Research Institute Heterocyclic compounds as biogenic amine transport modulators
US10087148B2 (en) * 2014-12-05 2018-10-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health Quinazolines as biogenic amine transport modulators
US20160159751A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
US9701677B2 (en) 2014-12-24 2017-07-11 Gilead Sciences, Inc. Fused pyrimidine compounds
US9624195B2 (en) 2014-12-24 2017-04-18 Gilead Sciences, Inc. Isoquinoline compounds
US10548898B2 (en) 2014-12-24 2020-02-04 Gilead Sciences Inc. Quinazoline compounds
US10206926B2 (en) 2014-12-24 2019-02-19 Gilead Sciences, Inc. Quinazoline compounds
US9730936B2 (en) 2014-12-24 2017-08-15 Gilead Sciences, Inc. Quinazoline compounds
US11304948B2 (en) 2014-12-24 2022-04-19 Gilead Sciences, Inc. Quinazoline compounds
US10772894B2 (en) 2015-03-13 2020-09-15 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN106045924A (zh) * 2016-07-28 2016-10-26 黑龙江八农垦大学 一种芳基取代喹唑啉胺衍生物的合成方法
WO2020021064A1 (fr) 2018-07-26 2020-01-30 Domain Therapeutics Dérivés de quinazolinone substitués et leur utilisation en tant que modulateurs allostériques positifs de mglur4
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
WO2022091029A1 (fr) * 2020-10-30 2022-05-05 Resverlogix Corp. Méthodes pour abaisser le taux d'hba1c avec une combinaison d'un inhibiteur de bromodomaine bet et d'un inhibiteur du transporteur de glucose dépendant du sodium 2
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1
CN112608302A (zh) * 2020-12-28 2021-04-06 郑州大学第一附属医院 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用
CN114315802A (zh) * 2021-12-14 2022-04-12 西安医学院 一种喹唑啉含氮杂环衍生物及制备方法和用途

Also Published As

Publication number Publication date
JP2008526734A (ja) 2008-07-24
EP1844023A1 (fr) 2007-10-17
KR20060079121A (ko) 2006-07-05

Similar Documents

Publication Publication Date Title
EP1844023A1 (fr) Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité
CN102548983B (zh) 作为单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺
US20080207614A1 (en) Quinazoline derivatives for the treatment and prevention of diabetes and obesity
CN101466714B (zh) 作为hm74a激动剂的嘌呤酮衍生物
CN102596923B (zh) 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
CN101531638B (zh) 用作***相关受体调节剂的化合物及其应用
CN101679365A (zh) 作为葡萄糖激酶激活剂的新型吡咯-2-甲酰胺衍生物、它们的制造方法和药学应用
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
MXPA06007715A (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad.
CA2437409C (fr) Azoles en inhibiteurs de la decarboxylase des malonyl-coa, convenant comme modulateurs metaboliques
DE602004009582T2 (de) Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
EA024703B1 (ru) Комбинация оланзапина и агониста taar1
TW201313708A (zh) 用於治療代謝性疾病與相關病症之單醯基甘油脂酶抑制劑
CN114014796A (zh) 一类依巴斯汀的盐及其制备方法和应用
US20090176780A1 (en) Nitrogenous heterocyclic compounds
CN101827595B (zh) 作为神经肽y2受体调节剂的取代的哌嗪和哌啶类
KR20030085005A (ko) 진양제
CN105367565B (zh) 哌嗪(啶)环己基衍生物及其治疗精神神经疾病的应用
KR101676889B1 (ko) 페닐이미다졸 화합물
KR20020067919A (ko) 신규 화합물
KR101123071B1 (ko) 신규 이미다졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 흑색종의 예방 및 치료용 약학적 조성물
CN105111151A (zh) 作为PPAR-γ调节剂的氨基嘧啶衍生物
US5116839A (en) Use of isoxazolin-3-one derivatives as antidepressants
US8431586B2 (en) Quinazoline derivatives and pharmaceutical compositions thereof
KR100556559B1 (ko) 2-(4-(4-(4,5-디클로로-2-메틸이미다졸-1-일)부틸)-1-피페라지닐)-5-플루오로피리미딘, 이것의 제조 방법 및 이것의치료적 용도

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007549270

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005823851

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005823851

Country of ref document: EP